BriaCell Therapeutics Corp. (V:BCT*CA)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: Bellevue Centre, 235 15th St 3rd Floor
Tel: N/A
IR: See website
Key People
Jamieson Bondarenko
Chairman of the Board
William V. Williams
President, Chief Executive Officer, Director
Charles Louis Wiseman
Co-Founder, Director
Gadi Levin
Chief Financial Officer, Corporate Secretary
Business Overview
BriaCell Therapeutics Corp. is a Canada-based immuno-oncology focused biotechnology company developing targeted approaches for the management of cancer. The Company, in collaboration with Incyte Corporation, is conducting a Phase I/IIa clinical trial of Bria-IMT in combination with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and manufacturing logistics associated with other personalized immunotherapies.
Financial Overview
For the nine months ended 30 April 2020, Briacell Therapeutics Corp revenues was not reported. Net loss increased 4% to C$4.2M. Higher net loss reflects Change in fair value of convertible debt decrease from C$393K (income) to C$79K (expense), Foreign exchange income (loss) decrease from C$40K (income) to C$20K (expense), Interest income decrease from C$12K (income) to C$0K.
Reporting Currency: Canadian Dollars
Enterprise value: $4.68M as of Apr 30, 2020
Annual revenue (TTM): $0.00M as of Apr 30, 2020
EBITDA (TTM): -$5.83M as of Apr 30, 2020
Net annual income (TTM): -$5.94M as of Apr 30, 2020
Free cash flow (TTM): -$1.94M as of Apr 30, 2020
Net Debt Last Fiscal Year: $0.22M as of Apr 30, 2020
Shares outstanding: 721,962 as of Apr 30, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization